Amniotic membrane is a dual-layered dehydrated human amnion membrane (dHAM) allograft composed primarily of a connective tissue matrix. It is minimally manipulated, preserving many of the natural growth factors and cytokines that are abundantly present in amniotic tissue. The presence of the connective tissue matrix and associated factors help to regenerate soft tissue while inhibiting inflammation and scar tissue formation.

Our amniotic membrane allograft is shelf-stable and minimally manipulated. Amniotic membrane has a long clinical history in managing diabetic wounds, burns and ocular repair. Research has shown that the membrane contains a variety of beneficial components including growth factors, heavy chain-hyaluronic acid and a scaffold which all reinforce its application as a protective covering.

Amniotic membrane is reimbursed by insurers and our team of billing experts will assist your staff with all prior authorization and billing questions.

Multiple studies show amniotic membrane has been successfully used in treatments for decades. Amniotic membrane has low levels of antigen expression and does not trigger an immune response.

It is regulated by the FDA as a biological tissue under Section 361 of the Public Health Service Act. The amniotic membrane is obtained through a voluntary donation after a C-section delivery. We use a U.S. based, AATB-accredited tissue recovery agency, which allows us to receive and process the donated placental tissue within a 24-hour period. Our patent-pending process is a highly manual and surgical harvesting procedure which generates the highest yield of amniotic tissues.